<DOC>
	<DOCNO>NCT00398125</DOCNO>
	<brief_summary>To investigate safety , tolerability anti-viral activity Integrase-Na√Øve HIV-1 infect adult</brief_summary>
	<brief_title>Monotherapy Versus Placebo Over 10 Days Integrase Naive HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion criterion : Documented HIV1 infection screen viral load 5000 300,000 copies/mL . Baseline CD4 cell count great 100 . Females must nonchildbearing potential Not receive antiretroviral therapy 12 week prior first dose . Exclusion criterion : Must infect hepatitis B C. Patients must acute laboratory abnormality . Must active CDC ( Centers Disease Control Prevention ) Category C disease ( 1993 ) , except cutaneous Kaposi 's sarcoma require systemic therapy trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>GSK364735</keyword>
	<keyword>HIV-1</keyword>
	<keyword>integrase inhibitor</keyword>
</DOC>